Abstract 573P
Background
Tumour infiltrating CD8+ cytotoxic T cells confer favourable prognosis in colorectal cancer (CRC). The added prognostic value of other immune cells is unclear.
Methods
We used multiparameter co-immunofluorescence to determine the density of CD8+, CD20+, FoxP3+ and CD68+ cells in the intraepithelial (IE) and intrastromal (IS) compartments in stage II/III CRCs from the SCOT and QUASAR2 trials. We determined marker prognostic and predictive value by Cox regression of SCOT cases, with validation in the QUASAR2 cohort.
Results
Our study included 2,340 SCOT and 1,069 QUASAR2 cases. Univariable analysis of recurrence-free interval (RFI) in SCOT revealed expected prognostic value of intraepithelial CD8 (CD8IE) (continuous variable: HR for cases at 75th vs 25th percentile (HR75vs25)= 0.73, 95% CI=0.68-0.79, P=2.5e-16) and, less expectedly FoxP3 within tumour stroma (FoxP3IS) (HR75vs25)= 0.71, 95% CI=0.64-0.78, P=1.5e-13), but not epithelium. CD8IE and FoxP3IS were independently prognostic in multivariable analysis, and a composite marker including both (CD8IE-Foxp3IS) was superior to either alone as a continuous variable (adjHR75vs25= 0.70; 95%CI=0.63–0.78; P=5.1e-11), and when categorised into three groups (Low/Int/High) using sample medians (Int vs High HR = 1.60, 95%CI=1.24–2.05, P=2.5e-04; Low vs High HR = 2.30, 95%CI=1.80–2.95; P=3.6e-11). These results were validated in the QUASAR2 trial. Pooled analysis of both studies revealed interactions between CD8IE-FoxP3IS and tumour sidedness (adjP INT=0.010), stromal proportion (adjP INT=0.018), and MMR status (adjP INT=0.079). CD8IE-FoxP3IS refined stage III risk groups, with clinical low risk (T1-3, N1), CD8IE-FoxP3IS low cases demonstrating similar 3-year recurrence-free probability to clinical high risk (T4 and/or N2), CD8IE-FoxP3IS high cases (79.2 vs 76.4%, adj log-rank P=0.16).
Conclusions
Combined evaluation of CD8IE and FoxP3IS is superior to single markers and refines CRC risk stratification. FoxP3IS prognostic value is inconsistent with an immunosuppressive role; further investigation of these cells as an immunotherapy target is merited.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
D.N. Church.
Funding
Cancer Research UK, National Institutes for Health Research, Promedica Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - The role of early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
Presenter: Jinjia Chang
Session: Poster session 10
594P - The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st- or 2nd-line chemotherapy
Presenter: Naoki Izawa
Session: Poster session 10
595P - The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)
Presenter: Jaume Capdevila Castillon
Session: Poster session 10
597P - Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance)
Presenter: Martin Weiser
Session: Poster session 10
598P - Influence of the early stoma closure after low rectal cancer resection on completeness of adjuvant chemotherapy (CoCStom): A randomized, controlled multicentre trial of the AIO (AIO KRK 0113)
Presenter: Flavius Sandra-Petrescu
Session: Poster session 10
599P - R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)
Presenter: Javier Carrasco
Session: Poster session 10